The joint letter on Atarulen (Translarna)

We are very happy to announce that EAMDA, United Parent Projects Muscular Dystrophy and European Organisation for Rare Diseases - EURORDIS have signed joint letter on Re-examine January 2014 Negative Opinion on Conditional Approval of Ataluren (Translarna) sent to Committee for Medicinal Products for Human Use at European Medicines Agency (EMA). The common effort resulted that EMA granted Conditional Approval for Ataluren (Translarna). The full version of the letter is reachable HERE.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our privacy policy.

I accept cookies from this site.

EU Cookie Directive Module Information